Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Will Serum Institute Join Strides, Gland On The Sputnik V Flight?

Around 550 Million Doses Tied Up So Far

Executive Summary

While speculation mounts about Serum Institute being next in line for an RDIF partnership, Gland Pharma and Strides unit Stelis sign up to make COVID-19 vaccine Sputnik V. Part of the 550 million dose output tied up from India so far could be consumed domestically, but exports are a possibility as demand from European countries is set to jump.

You may also be interested in...



Coronavirus Update: CoVIg-19 Alliance Ends As Trial Misses Endpoints

Global research consortium to investigate the use of immunoglobulin as a COVID-19 therapy ends following disappointing results from a Phase III trial. Meanwhile, Russian vaccine producer RDIF is snapping up more production capacity in India, where interferon has also progressed as a possible treatment. 

Coronavirus Update: Double-Mutant Strain Discovered, India Puts Temporary Hold On AZ Vaccine Exports

Concern in India as a double-mutant strain with E484Q and L452R escape mutations has been found in the state of Maharashtra.

Coronavirus Notebook: UK Tests Preventative Treatments As Row Escalates With EU Over Vaccine Supply

The procurement and authorization of vaccines are under scrutiny in the European Parliament this week. In the meantime, another Sputnik V spat is taking wing between Russia and the EU, while France has resumed the use of AstraZeneca’s vaccine, but only in the over-55s.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144039

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel